title: [Effectiveness on the vicryl pad in treatment of primary, recurrent and re-recurrent inguinal hernias--10 years experiences].
abstract: After testing the absorbable vicryl pad, which was developed by us in 1985, and having applied the technique as a routine in the surgical therapy of inguinal hernias since 1986, in total 2222 primary inguinal hernias and additional 937 first up to maximum 10th recurrences have been treated at our surgical department by means of the additional vicryl pad implantation. Within 5 to 9 years after surgery, follow-up examinations of the primary inguinal hernias (follow-up rate of 87.8%) showed a recurrence rate of 0.96%; with a follow-up rate of 91% for re- as well as rerecurrent hernias an extremely low re-recurrent rate of only 1.7% was found. By implantation of a vicryl pad the recurrent and rerecurrent rate could therefore be decisively minimized. The vicryl pad is inducing an additional connective tissue growth in the inguinal area of the body resulting in this high success rate.
authors.affiliation: Chirurgische Klinik, Kreiskrankenhaus Grevenbroich.
authors.forename: H R
authors.initials: HR
authors.lastname: Willmen
authors.forename: B
authors.initials: B
authors.lastname: Mies
authors.forename: M
authors.initials: M
authors.lastname: Nacken
authors.forename: H
authors.initials: H
authors.lastname: Höfken
mesh_terms: D019072:Antibiotic Prophylaxis; D005500:Follow-Up Studies; D005839:Gentamicins / Q000008:administration & dosage; D006552:Hernia, Inguinal / Q000601:surgery*; D006801:Humans; D011098:Polyglactin 910; D011183:Postoperative Complications / Q000601:surgery*; D019736:Prostheses and Implants; D012008:Recurrence; D012086:Reoperation; D013530:Surgical Wound Infection / Q000517:prevention & control; D013536:Suture Techniques
chemical_list: D005839:Gentamicins; D011098:Polyglactin 910